| Prev Close: | 45.80 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 48.65 |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | 21-Oct-13 |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 33.33 - 48.42 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 4,041,650 |
|---|
| Market Cap: | 72.61B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | N/A |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Merck Restructuring Plan To Save $2.5 Bil Lifts Stockat Investor's Business Daily(Tue, Oct 1)
- Why a Backup Plan Is No Plan at Allat Motley Fool(Tue, Oct 1)
- InPlay: AbbVie to present investigational data from Phase II hepatitis C program at The Liver Meeting; Phase III top-line results expected beginning later in 2013Briefing.com(Tue, Oct 1)
- AbbVie To Present Investigational Data From Phase II Hepatitis C Program At The Liver MeetingPR Newswire(Tue, Oct 1)
- Achillion Pharma Downgraded After Hepatitis C Setbackat Investor's Business Daily(Mon, Sep 30)
- Why Achillion Pharmaceuticals Inc. Shares Were Evisceratedat Motley Fool(Mon, Sep 30)
- Achillion Is Burnt Toastat Seeking Alpha(Mon, Sep 30)
- Achillion Falls on FDA Hold on Hepatitic C Medicineat Bloomberg(Mon, Sep 30)
- 5 Relatively Undervalued Dividend Fat Cats That Offer Reliable Retirement Incomeat Seeking Alpha(Sun, Sep 29)
- These 2 Hepatitis-C Drug Developers Are Getting Left in the Dustat Motley Fool(Sun, Sep 29)
- Meet the 2 Newest Investments in Cystic Fibrosisat Motley Fool(Sun, Sep 29)
- Achillion’s Hepatitis C Drug Still on Hold by U.S. FDAat Bloomberg(Fri, Sep 27)
- Big Pharma Competition Shouldn't Worry This Biotechat Motley Fool(Fri, Sep 27)
- Update on Gilead's PortfolioZacks(Fri, Sep 27)
- AbbVie's 3 Biggest Opportunitiesat Motley Fool(Thu, Sep 26)
Key Statistics
| Forward P/E (1 yr): | 14.22 |
|---|
| P/S (ttm): | 3.88 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 3.13 |
|---|
| Quarterly EPS Est
(Sep-13)
: | 0.78 |
|---|
| Mean Recommendation*: | 2.3 |
|---|
| PEG Ratio (5 yr expected): | 1.02 |
|---|
Business Summary
AbbVie Inc., a research-based biopharmaceutical company, engages in the discovery, development, manufacture, and sale of pharmaceutical products worldwide.
View More